Favorable regulatory landscape, including FDA’s promotion of alternatives to animal testing
Supportive environment for cell and gene therapy development
Unparalleled collaboration potential with world-leading IT and biotech companies
We have entered the U.S. to fully realize the potential of organoid technologies that began in Korea and are now ready to blossom on a global stage.
